Hummingbird Bioscience, a precision biotherapeutics company, has appointed Kon Yew Kwek, BM BCh, DPhil, and Lisa Ooi, PhD, as Chief Medical Officer and Chief Operating Officer, respectively.
Dr. Kon Yew Kwek, Chief Medical Officer
Kwek is promoted to Chief Medical Officer, from Senior Vice President of Clinical Development. He joined the company in 2022 and brings two decades of experience from Akeso Biopharma, Eli Lilly and IQVIA and clinical practice. He will lead the company’s clinical development from Singapore.
“I look forward to the next milestones in our clinical programs and progressing more of our pre-clinical pipeline to the clinic,” said Kwek.
Dr. Lisa Ooi, Chief Operating Officer
Ooi is promoted to Chief Operating Officer, from Senior Vice President of Strategy. She joined the company in 2022 and brings two decades of experience from Singapore’s government agencies and biopharma industry, including the Economic Development Board, Agency for Science, Technology and Research (A*STAR), ASLAN Pharmaceuticals and Bayer.
“I am delighted to lead the team’s strategy towards its next phase of growth, building upon our strong scientific capabilities and commitment to deeply understanding tumor biology. With our proprietary antibody and dual-payload ADC platform technologies, I look forward to what we will achieve in the coming year,” said Ooi.
Related News
Last year, Hummingbird Bioscience named Angèle Maki as Chief Business Officer.
